Scroll

procyclidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
muscarinic receptors agonists/antagonists	2276	77-37-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: procyclidine kemadrine tricoloid tricyclamol procyclidine hydrochloride procyclidine HCl	A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. Molecular weight: 287.45 Formula: C19H29NO CLOGP: 4.59 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.47 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

procyclidine
kemadrine
tricoloid
tricyclamol
procyclidine hydrochloride
procyclidine HCl

A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.

Molecular weight: 287.45
Formula: C19H29NO
CLOGP: 4.59
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.47
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O
25	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.16 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.74 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.86 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	30 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.09 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
July 27, 1955	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Schizophrenia	621.99	67.27	155	6544	9797	63472526
Jaundice cholestatic	457.05	67.27	114	6585	7210	63475113
Psychotic disorder	440.15	67.27	146	6553	25566	63456757
Hypomania	437.70	67.27	107	6592	6223	63476100
Hepatotoxicity	251.85	67.27	107	6592	36934	63445389
Blood bilirubin increased	251.57	67.27	107	6592	37033	63445290
Cholelithiasis	237.48	67.27	108	6591	43817	63438506
Gastric pH decreased	195.61	67.27	38	6661	736	63481587
Derealisation	173.05	67.27	37	6662	1171	63481152
H1N1 influenza	164.95	67.27	38	6661	1701	63480622
Cogwheel rigidity	160.24	67.27	38	6661	1932	63480391
Depersonalisation/derealisation disorder	157.32	67.27	35	6664	1337	63480986
Feeling of despair	153.75	67.27	38	6661	2301	63480022
Neuroleptic malignant syndrome	146.14	67.27	53	6646	12003	63470320
Dissociation	145.39	67.27	38	6661	2881	63479442
Asthma-chronic obstructive pulmonary disease overlap syndrome	138.07	67.27	34	6665	2027	63480296
Muscle rigidity	137.32	67.27	50	6649	11450	63470873
Drooling	134.80	67.27	38	6661	3830	63478493
Total lung capacity increased	134.22	67.27	34	6665	2276	63480047
Feeling of body temperature change	130.26	67.27	39	6660	4858	63477465
Muscle disorder	129.70	67.27	39	6660	4930	63477393
Dystonia	128.38	67.27	50	6649	13769	63468554
Menstrual disorder	122.89	67.27	38	6661	5275	63477048
Hallucinations, mixed	122.16	67.27	37	6662	4792	63477531
Paralysis	121.77	67.27	44	6655	9856	63472467
Incontinence	114.86	67.27	44	6655	11588	63470735
Parosmia	113.02	67.27	37	6662	6169	63476154
Therapeutic product ineffective	112.50	67.27	28	6671	1744	63480579
Serotonin syndrome	104.83	67.27	54	6645	28628	63453695
Nasal polyps	101.94	67.27	34	6665	6005	63476318
Mania	98.33	67.27	40	6659	12327	63469996
Sarcoidosis	96.45	67.27	34	6665	7088	63475235
Mydriasis	96.19	67.27	39	6660	11917	63470406
Sensory loss	94.92	67.27	37	6662	10201	63472122
Hypoaesthesia oral	92.94	67.27	39	6660	12994	63469329
Premature labour	91.12	67.27	38	6661	12466	63469857
Emotional disorder	88.64	67.27	38	6661	13341	63468982
Hepatic enzyme increased	87.37	67.27	107	6592	202221	63280102
Urinary retention	85.38	67.27	48	6651	30253	63452070
Feeling jittery	82.03	67.27	36	6663	13367	63468956
Rhinitis allergic	79.97	67.27	34	6665	11693	63470630
Nightmare	78.49	67.27	39	6660	19155	63463168
Dyskinesia	77.65	67.27	46	6653	31956	63450367
Mood swings	77.36	67.27	38	6661	18210	63464113
Cyanosis	77.01	67.27	37	6662	16898	63465425
Pallor	76.96	67.27	45	6654	30523	63451800
Restless legs syndrome	76.80	67.27	38	6661	18493	63463830
Cardiac murmur	72.93	67.27	34	6665	14518	63467805
Agitation	72.79	67.27	56	6643	59701	63422622
Bronchiectasis	69.57	67.27	34	6665	16108	63466215
Drug withdrawal syndrome	68.36	67.27	40	6659	27154	63455169

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tardive dyskinesia	98.75	30.79	28	1834	5762	34949307
Sedation	83.49	30.79	34	1828	20972	34934097
Neuroleptic malignant syndrome	61.03	30.79	26	1836	17908	34937161
Obesity	58.61	30.79	23	1839	12855	34942214
Vitamin B complex deficiency	51.51	30.79	10	1852	392	34954677
Neutrophil count increased	49.03	30.79	22	1840	17124	34937945
Blood folate decreased	47.02	30.79	10	1852	621	34954448
Orthostatic hypotension	43.21	30.79	23	1839	25896	34929173
Schizophrenia	41.26	30.79	16	1846	8650	34946419
Pseudoporphyria	39.83	30.79	8	1854	374	34954695
White blood cell count increased	35.76	30.79	24	1838	41127	34913942
Postoperative respiratory failure	33.79	30.79	6	1856	143	34954926
Psychotic disorder	33.31	30.79	19	1843	24433	34930636
Toxicity to various agents	32.22	30.79	46	1816	200316	34754753
Hepatitis A	32.07	30.79	7	1855	491	34954578

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Schizophrenia	607.59	40.17	167	8342	15273	79720606
Psychotic disorder	434.66	40.17	164	8345	41238	79694641
Hypomania	417.68	40.17	107	8402	7437	79728442
Jaundice cholestatic	406.71	40.17	114	8395	11170	79724709
Cholelithiasis	217.48	40.17	108	8401	52556	79683323
Hepatotoxicity	217.07	40.17	107	8402	51245	79684634
Neuroleptic malignant syndrome	207.66	40.17	86	8423	27473	79708406
Blood bilirubin increased	191.42	40.17	107	8402	66125	79669754
Gastric pH decreased	190.04	40.17	38	8471	848	79735031
Derealisation	161.15	40.17	37	8472	1612	79734267
Muscle rigidity	159.80	40.17	65	8444	19817	79716062
H1N1 influenza	150.51	40.17	38	8471	2481	79733398
Depersonalisation/derealisation disorder	146.27	40.17	35	8474	1827	79734052
Feeling of despair	146.24	40.17	38	8471	2783	79733096
Cogwheel rigidity	142.83	40.17	38	8471	3050	79732829
Total lung capacity increased	134.00	40.17	34	8475	2264	79733615
Dissociation	132.90	40.17	38	8471	3983	79731896
Menstrual disorder	132.47	40.17	38	8471	4029	79731850
Dystonia	132.09	40.17	58	8451	21341	79714538
Feeling of body temperature change	126.57	40.17	39	8470	5287	79730592
Drooling	126.56	40.17	40	8469	5894	79729985
Muscle disorder	123.92	40.17	39	8470	5668	79730211
Asthma-chronic obstructive pulmonary disease overlap syndrome	122.62	40.17	34	8475	3187	79732692
Hallucinations, mixed	112.69	40.17	38	8471	6861	79729018
Paralysis	112.48	40.17	45	8464	13132	79722747
Therapeutic product ineffective	109.91	40.17	28	8481	1894	79733985
Parosmia	108.15	40.17	37	8472	6977	79728902
Premature labour	105.41	40.17	38	8471	8352	79727527
Serotonin syndrome	104.14	40.17	63	8446	44964	79690915
Incontinence	102.59	40.17	43	8466	14121	79721758
Hepatic enzyme increased	100.36	40.17	110	8399	182500	79553379
Nasal polyps	95.11	40.17	34	8475	7293	79728586
Mania	92.10	40.17	43	8466	18217	79717662
Sarcoidosis	90.84	40.17	34	8475	8301	79727578
Hypoaesthesia oral	89.47	40.17	39	8470	14085	79721794
Dyskinesia	89.25	40.17	57	8452	44716	79691163
Sensory loss	85.98	40.17	37	8472	12954	79722925
Emotional disorder	85.55	40.17	38	8471	14349	79721530
Feeling jittery	83.11	40.17	36	8473	12805	79723074
Mydriasis	81.17	40.17	39	8470	17604	79718275
Mood swings	79.68	40.17	40	8469	19840	79716039
Rhinitis allergic	78.11	40.17	34	8475	12235	79723644
Restless legs syndrome	73.47	40.17	38	8471	20054	79715825
Urinary retention	72.65	40.17	55	8454	56575	79679304
Cardiac murmur	69.84	40.17	34	8475	15790	79720089
Nightmare	69.80	40.17	40	8469	25821	79710058
Swollen tongue	67.47	40.17	47	8462	42523	79693356
Cyanosis	62.79	40.17	37	8472	25145	79710734
Drug withdrawal syndrome	61.35	40.17	41	8468	34677	79701202
Pallor	60.65	40.17	47	8462	50015	79685864
Agitation	59.85	40.17	63	8446	99652	79636227
Vomiting	59.09	40.17	180	8329	665648	79070231
Bronchiectasis	58.74	40.17	34	8475	22352	79713527
Blood sodium decreased	58.11	40.17	39	8470	33216	79702663
Skin discolouration	55.17	40.17	41	8468	40993	79694886
Restlessness	54.91	40.17	43	8466	46449	79689430
Lung neoplasm malignant	54.42	40.17	35	8474	27757	79708122
Eye pain	51.54	40.17	38	8471	37540	79698339
Aphasia	50.44	40.17	41	8468	46691	79689188
Sedation	48.71	40.17	42	8467	51853	79684026
Limb injury	47.72	40.17	33	8476	29495	79706384
Speech disorder	46.97	40.17	42	8467	54403	79681476
Toxicity to various agents	46.08	40.17	123	8386	421417	79314462
Disorientation	45.60	40.17	44	8465	62732	79673147
Disturbance in attention	45.44	40.17	40	8469	50761	79685118
Pain	45.19	40.17	10	8499	703792	79032087
Swelling face	44.52	40.17	46	8463	71166	79664713
Illness	44.38	40.17	38	8471	46473	79689406
Tinnitus	43.90	40.17	37	8472	44296	79691583
Confusional state	43.37	40.17	101	8408	317896	79417983
Condition aggravated	42.04	40.17	133	8376	500991	79234888
Tardive dyskinesia	41.56	40.17	21	8488	10550	79725329
Drug ineffective	41.45	40.17	33	8476	1080880	78654999
Salivary hypersecretion	41.07	40.17	23	8486	14201	79721678

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04AA04	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Tertiary amines
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:66956	antidyskinetic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Urinary tract obstruction	contraindication	7163005	DOID:5200
Severe chronic ulcerative colitis	contraindication	14311001
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hiatal hernia	contraindication	84089009	DOID:12642
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Gastrointestinal obstruction	contraindication	126765001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Drowsy	contraindication	271782001
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastric ulcer	contraindication	397825006	DOID:10808
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.34	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	8.34	PDSP	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.60	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.91	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.62	PDSP
Glutamate [NMDA] receptor	Ion channel	O15399 O60391 Q05586 Q12879 Q13224 Q14957 Q8TCU5	NMDE4_HUMAN NMD3B_HUMAN NMDZ1_HUMAN NMDE1_HUMAN NMDE2_HUMAN NMDE3_HUMAN NMD3A_HUMAN		Ki	5.77	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.16	PDSP
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	5.17	CHEMBL

External reference:

ID	Source
4019907	VUID
N0000147992	NUI
D00782	KEGG_DRUG
60-48-0	SECONDARY_CAS_RN
1508-76-5	SECONDARY_CAS_RN
4018767	VANDF
4019907	VANDF
C0033254	UMLSCUI
CHEBI:8448	CHEBI
CHEMBL251903	ChEMBL_ID
CHEMBL86715	ChEMBL_ID
DB00387	DRUGBANK_ID
D011352	MESH_DESCRIPTOR_UI
4919	PUBCHEM_CID
7280	IUPHAR_LIGAND_ID
224	INN_ID
C6QE1Q1TKR	UNII
142443	RXNORM
5364	MMSL
d00969	MMSL
001643	NDDF
004666	NDDF
387199007	SNOMEDCT_US
387247001	SNOMEDCT_US
44990002	SNOMEDCT_US
CHEMBL2110635	ChEMBL_ID
CHEMBL1761	ChEMBL_ID

Pharmaceutical products:

None